1H FY2014 Business Results - IR osteoporosis, dementia, thrombosis and hypertension therapeutic medicine

Embed Size (px)

Text of 1H FY2014 Business Results - IR osteoporosis, dementia, thrombosis and hypertension therapeutic...

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved.

    1H FY2014 Business Results

    November 19, 2013

    Six months ended September 30, 2013

    FY2014: Fiscal year ending March 31, 2014

    (TSE 4326)

    INTAGE HOLDINGS Inc.

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 2

    Contents

     1H FY2014 Results

     1H FY2014 Progress and Future Issue

     FY2014 Earnings Forecast

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 3

     1H FY2014 Progress and Future Issue

     FY2014 Earnings Forecast

     1H FY2014 Results

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 4

    Consolidated Financial Highlights

    (Billions of yen)

    Net sales posted a record high, but were below target Operating income, recurring profit and net income all declined year-on-year from deceleration in the drug development solutions business

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 5

    Summary of Income Statements

    1H FY2013 Actual

    1H FY2014 Forecasts

    1H FY2014 Actual

    Change YoY

    Consolidated:

    Net Sales 18,148 19,765 18,505 +2.0%

    Operating Income 1,056 1,125 880 -16.7%

    Recurring Profit 996 1,003 811 -18.5%

    Net Income 499 485 363 -27.1%

    EPS (Yen)* 24.81 24.14 18.09 ―

    Non-Consolidated:

    Net Sales 12,889 13,712 13,144 +2.0%

    Operating Income 767 932 1,030 +34.2%

    Recurring Profit 877 1,069 1,251 +42.7%

    Net Income 533 709 873 +63.7% *On October 1, 2013 the Company implemented a stock split at a ratio of two shares for each share of common stock. The net

    income per share is calculated assuming this stock split took place at the beginning of the previous consolidated fiscal year.

    (Millions of yen)

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 6

    Summary of BS and CF Consolidated Balance Sheets Mar. 2013 Sept. 2013 Change Details Current assets 18,269 17,844 -425 Decrease in notes and accounts receivable-trade

    Noncurrent assets 11,128 10,990 -138 Decrease in lease assets, net

    Total assets 29,398 28,834 -563 ―

    Current liabilities 7,729 7,101 -628 Decrease in income taxes payable

    Noncurrent liabilities 6,174 6,131 -43 Decrease in lease obligation Total liabilities 13,904 13,232 -671 ―

    Shareholders’ equity 15,358 15,219 -138 Decreases in retained earnings Valuation and translation adjustments 74 267 +192 Deference of foreign translation adjustments

    Minority interests 61 115 +54 Increase in new consolidated subsidiaries

    Total net assets 15,493 15,602 +108 ―

    Consolidated Cash Flows 1H FY2013 1H FY2014 Change Details Cash flow from operating activities 1,458 990 -467 Year-on-year difference in social insurance premiums Cash flow from investing activities -811 -471 +340 Decrease in purchase of property and equipmentand intangible assets Cash flow from financing activities -275 -544 -268 Increase in repayment of short-term loans payable

    Effect of exchange rate changes on cash and cash equivalents -9 87 +96 ―

    Net increase/(decrease) in cash and cash equivalents 361 61 -299 ―

    Cash and cash equivalents at beginning of year 4,599 5,906 +1,306 ―

    Increase in cash and cash equivalents resulting from merger 109 ― -109 ―

    Cash and cash equivalents at end of year 5,070 5,967 +896 ―

    (Millions of yen)

    (Millions of yen)

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 7

    Net Sales by Segment

    16.60

    18.14 18.50

    [16%]

    [13%]

    [71%]

    [18%]

    [12%]

    [70%]

    [16%]

    [13%]

    [71%]

    (+19.9%)

    (-2.0%)

    (+9.0%)

    (-8.9%)

    (+7.9%)

    (+3.7%)

     Sales of SCI-personal (nationwide individual

    consumer panel data) and i-SSP (INTAGE Single Source Panel) rose

     New consolidated subsidiary JMIRI contributed to increased revenues

     Sales in global research in the ASEAN region

    increased.  INTAGE CHINA posted decreased sales as orders

    remained slack again following the previous term.

     Orders declined in both monitoring and data management and analysis services under intensified competition

     Sales from new and existing orders increased favorably with the recovery in Japanese corporate investment in IT systems.

     Drug Development Solutions

     System Solutions

     Marketing Research and Consulting

    (Billions of yen) ( ): Change YoY; [ ] Composition

    1H FY2012 1H FY20131H FY2011

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 8

    Breakdown of Sales of the Marketing Research and Consulting Segment

    Custom Research Traditional Research Models (Mail surveys, Interview surveys, etc.), Internet Research

    Syndicated Panel Services ・ SCI-personal (nationwide Individual

    consumer panel data) ・ i-SSP (single source panel) ・ SRI (FMCG retail panel data) ・ SDI (syndicated OTC drugs panel data) ・ SPI (In-store promotions effectiveness measurement) ・ SLI (syndicated female consumer panel data) ・JMIRI prescription information analysis service

    [37%]

    [63%]

    [39%]

    [61%]

    [40%]

    [60%]

    (+16.5%)

    (+4.7%)

    (+6.0%)

    (+2.2%)

    11.69

    12.75 13.22 Marketing Research and

    Consulting

    (Billions of yen) ( ): Change YoY; [ ] Composition

    1H FY2012 1H FY20131H FY2011

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 9

    Operating Income by Segment

    0.87

    1.05 0.88

     Profits rose on increased sales of SCI-

    personal and i-SSP.

     Profits increased from increase in sales for

    global research.  INTAGE CHINA posted decreased profits

    on worsened order conditions and increased operating costs for restructuring.

     Profits decreased from a decline in new orders and increased leading investment in international business.

     Profits increased from higher sales with improved order circumstances.

     Drug Development Solutions

     System Solutions

     Marketing Research and Consulting

    11/9期 12/9期 13/9期

    (Billions of yen)

    1H FY2012 1H FY20131H FY2011

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 10

     1H FY2014 Results

     1H FY2014 Progress and Future Issue

     FY2014 Earnings Forecast

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 11

    Basic Group Policy for FY2014

    Establish overwhelming competitive advantages in priority fields

    Ultimate customer relations and weapons to compete

    Keywords toward Growth

    Mobile

    Global

    Healthcare

    Create markets and capture share together with DOCOMO InsightMarketing, Inc.

    Group synergy strategy and rebuilding the story

    Accelerate global development by creating new weapons to compete

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved.

    Business Segments and Group Companies

    12

    Segments Group companies

    Marketing research and consulting 1. Syndicated Panel Services

    • Consumer panel data • Retail panel data • Other panel data

    2. Customized research • Internet research • Traditional Research Model (Interviews, qualitative research, MROC, CLT, etc.)

    INTAGE Inc. INTAGE RESEARCH Inc. INTAGE NAGANO Inc. ANTERIO Inc. Japan Medical Information Research Institute Inc. PLAMED Inc. DOCOMO InsightMarketing, INC. (an equity method affiliate) INTAGE CHINA Inc. INTAGE (Thailand) Co., Ltd. FTA Research and Consultant, LLC INTAGE INDIA Private Limited INTAGE SINGAPORE PTE. LTD. Consumer Search Hong Kong Limited * PT. INTAGE INDONESIA *

    System solutions Software development and sales System administration, maintenance and management Data center administration

    INTAGE Inc. INTAGE NAGANO Inc.

    Drug Development Solutions CRO ・Clinical monitoring ・Data management and analysis

    ASKLEP Inc. RPS Asklep Inc.* ASKLEP CHINA Inc. ASKLEP TAIWAN Inc. ASKLEP KOREA Inc.

    (21 companies, incl. INTAGE HLD and INTAGE ASSOCIATES)

    (14 companies)

    (Two companies)

    (Five companies)

    *Consolidated from this period

  • Copyright© 2013 INTAGE HOLDINGS Inc. All Rights Reserved. 13

    1H FY2014 Progress

    [INTAGE Inc.] Cross media (i-SSP) succeeded in expanding windows in agencies and mass media, and sales increased In the consulting field, new business development overseas related orders were received, securing sales above the target Received large systems orders in the financial, travel and health information fields Competitive advantages in publication POS service by expanding data, and value improvement made users beyond 120 companies [ASKLEP Inc.] Large decline in new orders from intensified competition Joint venture with RPS delayed because of RPS acquisition and merger [DOCOMO Insight Marketing Inc.] Consumer panel trial adopted by multiple companies [INTAGE RESEARCH Inc.]. Received large public orders from government organs which will contribute to sales from the second half [ANTERIO Inc.] While the market scale for Impact Track contracted from price competition, the simplif